Genmab — Oktober 2018

[E_L]

(End)

[Bulder]

Tak E L.
41% ORR heraf 1 CR - er det godt?

[Bulder]

Tyder på bedre responsrate end i rapporten fra sidste år (32%)

[Darvin]

Thanks E L - lidt forvirret. ORR er højere end sidst men median ser ud til at være kortere.

[JørgenVarnæs]

Kom N=34 resultaterne ikke fra dose eskaleringen_

[Bulder]

Hvad var responsvarigheden sidst?

[E_L]

So, standard of care beyond 1L treatment and 2L response rates of ∼13%

[E_L]

Last year n=34, investigator assessed ORR 32% (26% confirmed) median age 44

[E_L]

Now n=55, investigator assessed ORR 41% (24% confirmed) median age 47

[Bulder]

Do you happen to know the duration of response last year?

[Bulder]

Nevertheless, 41% is far better than 13%

[Bulder]

The 41% ORR was found by IIR (independent imaging review ) and not INV as far as I can see.

[E_L]

found last year https://oncologypro.esmo.org/Meeting-Resources/ESMO-2017-Congress/A-Phase-IIa-Study-of-Tisotumab-Vedotin-HuMax-R-TF-ADC-in-Patients-With-Relapsed-Recurrent-and-or-Metastatic-Cervical-Cancer

[E_L]

10.34 you are correct

[bibob]

@Bulder. - whats the different. ?

[Bulder]

Tx. But it doesn't tell us duration og response. Darvin, What do you mean by "median" looks shorter?

[Bulder]

Bibob, I think IIR is more stringent, without possible bias.

[bibob]

Ok. Thanks.

[Bulder]

Er der nogen der har overblik over, hvad der kunne være af muligheder for abstracts under de finere kategorier, hvor der også er noget mundtlig fremlæggelse?

[Bulder]

Jeg tænker f.eks. på Lyra-studiet dara-CyBorD i MM, som vi ikke har hørt en lyd om.